Status:
NOT_YET_RECRUITING
Memantine Hydrochloride in Prostate Cancer Patients
Lead Sponsor:
Bin Xu
Collaborating Sponsors:
The First People's Hospital of Lianyungang
Conditions:
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Prostate Cancer
Eligibility:
MALE
18+ years
Phase:
PHASE2
Brief Summary
The goal of this clinical trial is to learn if long-term use of memantine hydrochloride can treat, prevent, or correct castration resistance and drug resistance in advanced prostate cancer. The study ...
Eligibility Criteria
Inclusion
- Age ≥ 18 years
- Patients with metastatic castration-resistant prostate cancer (mCRPC) who have failed one or two prior lines of therapy. Patients with concomitant Alzheimer's disease will be prioritized for enrollment.
- Complete clinical baseline data must be available, and the patient must be willing to undergo long-term follow-up.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
Exclusion
- Patients with metastatic prostate cancer at initial diagnosis who have not progressed to mCRPC.
- Patients with a concurrent primary malignancy at another site.
Key Trial Info
Start Date :
November 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2028
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT07164794
Start Date
November 1 2025
End Date
June 1 2028
Last Update
November 19 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.